There are currently 852 clinical trials in Jacksonville, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic in Florida, Mayo Clinic - Jacksonville, Mayo Clinic and Mayo Clinic Florida. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer
NCT05683691
Recruiting
The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer.
Gender:
Male
Ages:
50 years and above
Trial Updated:
06/04/2024
Locations: Kasraeian Urology, Jacksonville, Florida
Conditions: Prostate Cancer
Register for Updates
Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia
NCT04447989
Recruiting
This is a multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study of sildenafil in premature infants (inpatient in Neonatal Intensive Care Units (NICUs)) with severe bronchopulmonary dysplasia (BPD).
Gender:
All
Ages:
29 weeks and below
Trial Updated:
06/04/2024
Locations: University of Florida Jacksonville Shands Medical Center, Jacksonville, Florida +1 locations
Conditions: Bronchopulmonary Dysplasia of Newborn
Register for Updates
Evaluation of Tonabersat for DME
NCT05727891
Recruiting
This randomized clinical trial will evaluate the effect of tonabersat compared with placebo on central subfield thickness (CST) in eyes with center-involved diabetic macular edema (CI-DME) and good visual acuity.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: University of Florida- Jacksonville, Jacksonville, Florida
Conditions: Diabetic Macular Edema
Register for Updates
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
NCT04214249
Recruiting
This phase II trial studies how well cytarabine and idarubicin or daunorubicin with or without pembrolizumab work in treating patients with newly-diagnosed acute myeloid leukemia. Chemotherapy drugs, such as cytarabine, idarubicin, and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune sy... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/04/2024
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy
Register for Updates
ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD
NCT03911505
Recruiting
This is a Phase 3, open-label, multicenter study to evaluate the safety, PK, efficacy, PD, and immunogenicity of Cipaglucosidase Alfa/Miglustat treatment in enzyme replacement therapy (ERT)-experienced and ERT-naïve pediatric subjects with Pompe disease, aged 0 to < 18 years
Gender:
All
Ages:
Between 0 years and 17 years
Trial Updated:
06/04/2024
Locations: Wolfson Children's Hospital, Jacksonville, Florida
Conditions: Pompe Disease (Late-onset)
Register for Updates
RA-PRO PRAGMATIC TRIAL
NCT04692493
Recruiting
The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in patients with active RA despite the use of a TNFi-biologic. In practice, most patients receive another... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: Mayo Clinic Jacksonville, Jacksonville, Florida
Conditions: Rheumatoid Arthritis
Register for Updates
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
NCT05329766
Recruiting
The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. Chemotherapy will consist of FOLFOX (oxaliplatin, leucovorin, fluorouracil).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: Mayo Clinic - Jacksonville, Jacksonville, Florida
Conditions: Gastrointestinal Tract Malignancies
Register for Updates
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT06161571
Recruiting
The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/04/2024
Locations: Akero Clinical Study Site, Jacksonville, Florida
Conditions: NASH/MASH, NAFLD/MASLD
Register for Updates
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NCT06215716
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/04/2024
Locations: Akero Clinical Study Site, Jacksonville, Florida
Conditions: NASH With Fibrosis, MASH With Fibrosis
Register for Updates
A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease
NCT06031844
Recruiting
This Phase 2a clinical trial will evaluate the effectiveness, safety, and tolerability of increasing dose strengths of an oral daily medication, DFV890, administered for 12 weeks, to reduce key markers of inflammation related to CVD risk, such as IL-6 and IL-18, in approximately 24 people with known heart disease and an elevated marker of inflammation, hsCRP.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/03/2024
Locations: University of Florida -Jacksonville UF Health Jacksonville, Jacksonville, Florida
Conditions: Coronary Heart Disease
Register for Updates
Amulet™ ADVANCE LAA
NCT05997446
Recruiting
This is a prospective, multicenter, observational study intended to characterize real-world outcomes on the commercially available Amulet device in the United States. The study will enroll approximately 1000 subjects at up to 50 US clinical sites. Subjects will be followed through 24 months in accordance with each site's standard care practices.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Baptist Medical Center, Jacksonville, Florida
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
NCT05583227
Recruiting
A randomized, double-blind, placebo-controlled multicenter, phase 3 study to evaluate the efficacy and safety of tezepelumab administered subcutaneously (SC) using an accessorized pre-filled syringe (APFS) versus placebo in adult and adolescent patients with eosinophilic esophagitis (EoE).
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
06/03/2024
Locations: Research Site, Jacksonville, Florida
Conditions: Eosinophilic Esophagitis
Register for Updates